Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Van Andel Institute Establishes Global Epigenetics Research Hub

Published: Wednesday, February 26, 2014
Last Updated: Wednesday, February 26, 2014
Bookmark and Share
Institute announces the establishment of a global epigenetics research hub, tapping into a hot-button research topic responsible for new and innovative approaches to personalized cancer therapy.

Epigenetics is widely regarded as the most significant new area of cancer research; it is the study of heritable changes in gene activity which are not caused by changes in the DNA sequence. The term epigenetics literally means “above” or “on top of” genetics, referring to external modifications to DNA that can turn genes “on” or “off.”

Leading this effort is Peter A. Jones Ph.D., D.Sc., Director of Research, Chief Scientific Officer of Van Andel Research Institute. Dr. Jones is a renowned researcher with more than 40 years’ experience in academia in the field of biomolecular research. Dr. Jones’ recent research has focused on epigenetics and how epigenetic therapies might benefit those living with cancer. He is based in the global headquarters of Van Andel Institute in Grand Rapids, Michigan and is driving the focus of epigenetic research among the Institute’s research partners in the U.S., U.K., Europe, Asia and around the world.

Dr. Jones’ aggressive blueprint for progress includes developing a consortium of five academic institutions – four in the U.S. and one abroad – which will carry on the work of developing epigenetic therapies that can be applied to human beings. The concept of collaboration plays a primary role in Dr. Jones’ strategy of creating a focus on epigenetics at the Institute. It is a notion that Dr. Jones has cultivated throughout his career, working alongside diverse teams of researchers, geneticists, chemists, oncologists, surgeons and assorted specialists.

“With the appointment of Dr. Jones, a visionary leader in biomedical research, Van Andel Institute is now a global stronghouse in epigenetics, one of the most significant fields in cancer research,” said David Van Andel, Chairman and CEO, Van Andel Institute. “We are embracing this field of study, and will extol epigenetics to a hurting world that is hungry for answers. At Van Andel Institute, we bank on sound science that precedes us, and embrace others who share our vision, and that includes ‘disruptors’ who are not afraid to say that we are impatient for new breakthroughs. Paired with our translational research that is speeding the delivery of new therapies from research bench to bedside, the establishment of an epigenetics hub with Dr. Jones at the helm will impact millions of lives, developing new epigenetic therapies for cancer and neurodegenerative diseases.”

Dr. Jones plans to bolster the Institute’s impressive research portfolio in cancer, neurodegenerative and other diseases as he continues his translational research in epigenetics. “Van Andel Institute is dedicated to changing the course of biomedical research and as I lead our new epigenetics hub, I have already begun to build a robust clinical program, am recruiting outstanding scientists and plan to continue to ensure exceptional science,” said Dr. Jones.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Tuesday, July 28, 2015
Prognostic Role Found for miR-21 Expression in Triple-Negative Breast Cancer
Findings suggest measurement of changes in the tumor microenvironment are important in this heterogeneous group.
Wednesday, December 03, 2014
Van Andel Research Institute Findings Provide More Complete Picture of Kidney Cancer
Two recent studies distinguish cancer subtypes and provide promising new drug targets, which could pave the way for better treatments.
Tuesday, January 03, 2012
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos